Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Asian Journal of Andrology ; (6): 432-437, 2018.
Artigo em Inglês | WPRIM | ID: wpr-1009609

RESUMO

The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml-1), intermediate (100-999 ng ml-1), and high (≥1000 ng ml-1). All patients received androgen deprivation therapy (ADT) immediately. We investigated PSA progression-free survival (PFS) for first-line ADT and overall survival (OS) within each of the three groups. Furthermore, we analyzed response to antiandrogen withdrawal (AW) and alternative antiandrogen (AA) therapies after development of castration-resistant prostate cancer (CRPC). No significant differences in OS were observed among the three groups (P = 0.654). Patients with high PSA levels had significantly short PFS for first-line ADT (P = 0.037). Conversely, patients in the high PSA level group had significantly longer PFS when treated with AW than those in the low PSA level group (P = 0.047). Furthermore, patients with high PSA levels had significantly longer PFS when provided with AA therapy (P = 0.049). PSA responders to AW and AA therapies had significantly longer survival after CRPC development than nonresponders (P = 0.011 and P < 0.001, respectively). Thus, extremely high PSA level predicted favorable response to vintage sequential ADT and AW. The current data suggest a novel aspect of extremely high PSA value as a favorable prognostic marker after development of CRPC.


Assuntos
Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Antagonistas de Androgênios/uso terapêutico , Progressão da Doença , Prognóstico , Intervalo Livre de Progressão , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/mortalidade , Resultado do Tratamento
2.
Asian Journal of Andrology ; (6): 111-115, 2002.
Artigo em Inglês | WPRIM | ID: wpr-284062

RESUMO

<p><b>AIM</b>To evaluate the occurrence and prevalence of microdeletions in the gamma chromosome of patients with azoospermia.</p><p><b>METHODS</b>DNA from 29 men with idiopathic azoospermia was screened by polymerase chain reaction (PCR) analysis with a set of gamma chromosome specific sequence-tagged sites (STSs) to determine microdeletions in the gamma chromosome.</p><p><b>RESULTS</b>Deletions in the DAZ (deleted in azoospermia) loci sgamma254 and sgamma255 were found in three patients with idiopathic azoospermia, resulting in an estimated frequency of deletions of 10.7% in idiopathic azoospermia men.</p><p><b>CONCLUSION</b>We conclude that PCR analysis is useful for the diagnosis of microdeletions in the Y chromosome, which is important when deciding the suitability of a patient for assisted reproductive technology such as testicular sperm extracion-intracytoplasmic sperm injection (TESE-ICSI).</p>


Assuntos
Adulto , Humanos , Masculino , Sequência de Bases , Cromossomos Humanos Y , Primers do DNA , Eucromatina , Genética , Hormônio Foliculoestimulante , Sangue , Heterocromatina , Genética , Hormônio Luteinizante , Sangue , Oligospermia , Sangue , Genética , Reação em Cadeia da Polimerase , Prolactina , Sangue , Deleção de Sequência , Genética , Sitios de Sequências Rotuladas , Testosterona , Sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA